Immune-humanized mouse models


IMODI’s Humanized mouse models are refined tools to study the impact of the human immune system in preclinical oncology:

  • Assessment of pharmacological profile and mechanism of action of immune-oncology compounds
  • Evaluation of antitumor activity related to antibody dependent cell cytotoxicity (ADCC)
  • Identification of biomarkers related to immunomodulators compounds efficacy

Humanized models can be specifically adapted to your needs:

Selection of the right model of humanized mice, depending on your target, your molecule and the question you have:

  • Human hematopoietic cells from healthy or pathological blood donors
  • hPMBC* in C.B-17 SCID, NOD-SCID, or NOG mice
  • CD34-positive HSC² in CIEA NOG mouse®, NSG, , BRGS
  • Purified hNK3cells in transgenic IL2-NOG and IL15-NOG mice
  • Cohorts of mice bearing both established PDX tumors and human immune cells
  • IMODI immune-humanized models are integrated and available via the X-Mice® platform of Oncodesign

The other benefits that humanized models can offer:

  • Increasing the success rate of establishment of hematological cancer PDX models
  • Studying inflammation, auto-immune diseases related to cancer pathologies
  • An extensive panel of other research applications:
    • Study of hematopoiesis,
    • Analysis of innate and adaptive immunity,
    • GvHD (Graft versus Host Disease),
    • Autoimmune disease,
    • Allergy,
    • Inflammation,
    • Infectious disease (HIV),
    • Vaccine development,
    • Transplantation,
    • Toxicology
(1) hPBMC: human peripheral bloodmononuclear cells
(2) HSC: hematopoietic stem cells
(3) UCB: umbilical cord blood
(4) hNK: human natural killer

Chi-Mice® is part of a comprehensive portfolio and translational rodent models and services offered by Oncodesign®
For more information email:
efang@oncodesign.com
www.oncodesign.com
oncodesign-small
Oncodesign® Biotechnology was founded by Dr Philippe Genne in Dijon, France, in 1995 to discover new and effective approaches to cancer treatment.
To reach this objective, we have developed two strategic activities: Experimentation of new cancer therapies (fee-for-service) and drug / biomarker Discovery programs in partnership with the pharmaceutical industry.

Contact